Trial Profile

A Phase 3 spasm frequency, placebo-controlled, parallel group study of Nabiximols in patients with Multiple Sclerosis spasticity(nabiximols responders)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jul 2020 New trial record
30 Jun 2020 According to a GW Pharmaceuticals media release, Five new MS Spasticity Phase 3 trials are expected to commence in H2 2020 (2) and H1 2021 (3), any one of which could enable a NDA submission in as early as 2021.
30 Jun 2020 According to a GW Pharmaceuticals media release, the company will host a webcast today to provide insight into the U.S. Phase 3 clinical program and commercial opportunity for nabiximols.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com